Faster Medicare Coverage Looms
- U.S. regulators proposed a faster Medicare coverage pathway for certain FDA breakthrough-designated devices. - The proposal would apply to selected Class II and Class III devices that already have FDA breakthrough status. - Shortening the payment lag could speed adoption of digital and molecular diagnostics, though evidence requirements remain crucial (statnews.com).
Medicare and the Food and Drug Administration said on April 23 they will launch a faster coverage track for some newly authorized medical devices, shortening the gap between federal clearance and payment. (cms.gov) The new program is called RAPID, short for Regulatory Alignment for Predictable and Immediate Device coverage. CMS said it will issue a proposed national coverage determination the same day an eligible device gets Food and Drug Administration market authorization. (cms.gov) The pathway applies to selected Class II and Class III devices with Food and Drug Administration Breakthrough Device designation. CMS and the Food and Drug Administration said Class II products must be in the Total Product Life Cycle Advisory Program, while Class III products can qualify whether or not they are in that program. (fda.gov) Medical devices are grouped by risk, with Class I at the low end and Class III at the high end. The Food and Drug Administration says Class III devices face the most stringent controls, while Breakthrough designation is reserved for devices aimed at life-threatening or irreversibly debilitating conditions. (fda.gov, fda.gov) The main policy change is earlier coordination on evidence. CMS said its staff will join manufacturers and Food and Drug Administration reviewers earlier in development so clinical studies can be designed to answer both approval questions and Medicare coverage questions. (fda.gov) That addresses a long-running problem in device regulation: a company can win Food and Drug Administration authorization and still wait months or longer for a Medicare coverage decision. CMS said RAPID is meant to reduce those delays by synchronizing authorization with the national coverage determination process. (cms.gov) This is not Medicare coverage for every new device on day one. CMS said the program is limited to devices that address unmet needs for Medicare beneficiaries, and the agency tied the pathway to the statutory national coverage determination process rather than creating automatic payment. (cms.gov) The announcement also builds on a narrower Medicare pathway finalized in 2024, called Transitional Coverage for Emerging Technologies. That program is voluntary, applies to certain Food and Drug Administration-designated breakthrough devices, and uses national coverage determinations and coverage with evidence development to speed review while keeping evidence requirements in place. (cms.gov, cms.gov) For device makers, the practical prize is predictability: they can learn earlier what outcomes matter for Medicare patients and what data CMS will want to see. For hospitals and doctors, the effect could be faster adoption of eligible diagnostics and other devices if the evidence package is ready when authorization arrives. (fda.gov, cms.gov) The next step is implementation: CMS and the Food and Drug Administration said RAPID starts now as an interagency pathway, but each device still has to clear the Food and Drug Administration and move through Medicare’s coverage process. (fda.gov, cms.gov)
